Антидоты при опиоидных отравлениях: поиск направлений их модификации (обзор литературы)

Уникальные физико-химические и фармакологические свойства синтетических наркотиков обусловливают заболеваемость и смертность, связанные с их употреблением. Среди последствий, возникающих в результате злоупотребления сильнодействующими опиоидами или в случае масштабного поражения при их использовании в качестве химического оружия, появляется необходимость увеличения дозы и кратности использования конкурентного антагониста налоксона, единственного доступного в настоящее время средства для купирования передозировки. Нами будут рассмотрены имеющиеся в общемировой практике средства для купирования опиоидных отравлений, обсуждена необходимость внедрения более мощных опиоидных антагонистов быстрого и длительного действия и представлены возможные направления функционализации опиоидных лигандов морфинанового типа.

1. Algera M. H., Kamp J., van der Schrier R. et al. Opioid-induced respiratory depression in humans: a review of pharmacokinetic-pharmacodynamic modelling of reversal // Br J Anaesth. – 2019. – Vol. 122, № 6. – e168–e179. https://doi.org/10.1016/j.bja.2018.12.023.

2. Bentley K. W., Boura A. L., Fitzgerald A. E. et al. Compounds possessing morphine-antagonizing or powerful analgesic properties // Nature. – 1965. – Vol. 206. – P. 102–103. https://doi.org/10.1038/206102a0.

3. Bird H. E., Huhn A. S., Dunn K. E. Fentanyl absorption, distribution, metabolism, and excretion: narrative review and clinical significance related to illicitly manufactured fentanyl // J Addict Med. – 2023. – Vol. 17, № 5. – P. 503–508. https://doi.org/10.1097/ADM.0000000000001185.

4. Blane G. F., Boura A. L., Fitzgerald A. E. et al. Actions of etorphinehydrochloride, (M99): a potent morphine-like agent // Br J Pharmacol Chemother. – 1967. – Vol. 30. – P. 11–22. https://doi.org/10.1111/j.1476-5381.1967.tb02108.x.

5. Boyer E. W. Management of opioid analgesic overdose // N Engl J Med. – 2012. – Vol. 367, № 2. – P. 146–155. https://doi.org/10.1056/NEJMra1202561.

6. Broadbear J. H., Sumpter T. L., Burke T. F. et al. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine // J Pharmacol Exp Ther. – 2000. – Vol. 294, № 3. – P. 933–940.

7. Crabtree B. L. Review of naltrexone, a long-acting opiate antagonist // Clin Pharm. – 1984. – Vol. 3, № 3. – P. 273–280.

8. Crystal R., Ellison M., Purdon C. et al. Pharmacokinetic Properties of an FDA-approved Intranasal Nalmefene Formulation for the Treatment of Opioid Overdose // Clin Pharmacol Drug Dev. – 2024. – Vol. 13, № 1. – P. 58–69. https://doi.org/10.1002/cpdd.1312.

9. Cueva J. P., Roche C., Ostovar M. et al. C7β-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors // J Med Chem. – 2015. – Vol. 58, № 10. – P. 4242–4249. https://doi.org/10.1021/acs.jmedchem.5b00130.

10. Edinoff A. N., Nix C. A., Reed T. D. et al. Pharmacologic and clinical considerations of nalmefene, a long duration opioid antagonist, in opioid overdose // Psychiatry Int. – 2021. – Vol. 2, № 4. – P. 365–378. https://doi.org/10.3390/psychiatryint2040028.

11. Fairbairn N., Coffin P. O., Walley A. Y. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic // Int J Drug Policy. – 2017. – Vol. 46. – P. 172–179. https://doi.org/10.1016/j.drugpo.2017.06.005.

12. France C. P., Ahern G. P., Averick S. et al. Countermeasures for preventing and treating opioid overdose // Clin Pharmacol Ther. – 2021. – Vol. 109, № 3. – P. 578–590. https://doi.org/10.1002/cpt.2098.

13. Gillis E. P., Eastman K. J., Hill M. D. et al. Application of fluorine in medicinal chemistry // J Med Chem. – 2015. – Vol. 58, № 21. – P. 8315–8359. https://doi.org/10.1021/acs.jmedchem.5b00258.

14. Harper M. H., Hickey R. F., Cromwell T. H. et al. The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man // J Pharmacol Exp Ther. – 1976. – Vol. 199, № 2. – P. 464–468.

15. Harris K., Page C. B., Samantray S. et al. One single large intramuscular dose of naloxone is effective and safe in suspected heroin poisoning // Emerg Med Austral. – 2020. – Vol. 32, № 1. – P. 88–92. https://doi.org/10.1111/1742-6723.13344.

16. Hart E. R., McCauley E. L. The pharmacology of N-allylnormorphine as compared with morphine // J Pharmacol Exp Ther. – 1944. – Vol. 82. – P. 339–348.

17. Hill L. G., Zagorski C. M., Loera L. J. Increasingly powerful opioid antagonists are not necessary // Int J Drug Policy. – 2022. – Vol. 99. – P. 103457. https://doi.org/10.1016/j.drugpo.2021.103457.

18. Hill R., Santhakumar R., Dewey W. et al. Fentanyl depression of respiration: comparison with heroin and morphine // Br J Pharmacol. – 2020. – Vol. 177, № 2. – P. 254–265. https://doi.org/10.1111/bph.14860.

19. Husbands S. M., Lewis J. W. Opioid ligands having delayed long-term antagonist activity: potential pharmacotherapies for opioid abuse // Mini Rev Med Chem. – 2003. – Vol. 3, № 2. – P. 137–144. https://doi.org/10.2174/1389557033405395.

20. Infante A. F., Elmes A. T., Gimbar R. P. et al. Stronger, longer, better opioid antagonists? Nalmefene is NOT a naloxone replacement // Int J Drug Policy. – 2024. – Vol. 124. – P. 104323. https://doi.org/10.1016/j.drugpo.2024.104323.

21. Jimenez V. M. Jr., Castaneda G., France C. P. Methocinnamox reverses and prevents fentanyl-induced ventilatory depression in rats // J Pharmacol Exp Ther. – 2021. – Vol. 377, № 1. – P. 29–38. https://doi.org/10.1124/jpet.120.000387.

22. Jordan C. G., Kennalley A. L., Roberts A. L. et al. The potential of methocinnamox as a future treatment for opioid use disorder: a narrative review // Pharmacy (Basel). – 2022. – Vol. 10, № 3. – P. 48. https://doi.org/10.3390/pharmacy10030048.

23. Kiyatkin E. A. Respiratory depression and brain hypoxia induced by opioid drugs: morphine, oxycodone, heroin, and fentanyl // Neuropharmacology. – 2019. – Vol. 151. – P. 219–226. https://doi.org/10.1016/j.neuropharm.2019.02.008.

24. Lewis J., Smith C., McCarthy P. et al. New 14-aminomorphinones and codeinones // NIDA Research Monograph. – 1988. – Vol. 90. – P. 136–143.

25. Lombardi J., Villeneuve E., Gosselin S. In response to: “the evolution of recommended naloxone dosing for opioid overdose by medical specialty” // J Med Toxicol. – 2016. – Vol. 12, № 4. – P. 412–413. https://doi.org/10.1007/s13181-016-0591-3.

26. Maguire D. R., France C. P. Behavioral pharmacology of methocinnamox: A potential new treatment for opioid overdose and opioid use disorder // J Exp Anal Behav. – 2023. – Vol. 119, № 2. – P. 392–406. https://doi.org/10.1002/jeab.831.

27. Mann J., Samieegohar M., Chaturbedi A. et al. Development of a translational model to assess the impact of opioid overdose and naloxone dosing on respiratory depression and cardiac arrest // Clin Pharmacol Ther. – 2022. – Vol. 112, № 5. – P. 1020–1032. https://doi.org/10.1002/cpt.2696.

28. Miller M. W., Wild M. A., Lance W. R. Efficacy and safety of naltrexone hydrochloride for antagonizing carfentanil citrate immobilization in captive Rocky Mountain elk (Cervus elaphus nelsoni) // J Wildl Dis. – 1996. – Vol. 32, № 2. – P. 234–239.

29. Nieland N. P., Moynihan H. A., Carrington S. et al. Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones // J Med Chem. – 2006. – Vol. 49, № 17. – P. 5333–5338. https://doi.org/10.1021/jm0604777.

30. Purser S., Moore P. R., Swallow S. et al. Fluorine in medicinal chemistry // Chem Soc Rev. – 2008. – Vol. 32, № 16. – P. 320–330. https://doi.org/10.1039/b610213c.

31. Sandulenko I. V., Ambartsumyan A. A., Moiseev S. K. Fluorinated and [18F] fluorinated morphinan based opioid ligands // Org Biomol Chem. – 2020. – Vol. 18, № 29. – P. 5533–5557. https://doi.org/10.1039/d0ob00619j.

32. Sandulenko I. V., Belozertseva I. V., Zvartau E. E. et al. C(21)-fluorinated thevinol scaffold for opioid ligands. 21,21,21-Trifluoro-6-O-nororvino ls: Design, synthesis and analgesic activity // Eur J Med Chem. – 2023. – Vol. 252. – P. 115296. https://doi.org/10.1016/j.ejmech.2023.115296.

33. Sandulenko I. V., Kovaleva E. S., Peregudov A. S. et al. 21,21,21-Trifluorothevinone: the straightest way to fluorinated thevinols and orvinols // ChemistrySelect. – 2016. – Vol. 1, № 5. – P. 1004–1005. https://doi.org/10.1002/slct.201600233.

34. Sandulenko I. V., Kovaleva E. S., Zelentsova M. V. et al. Control of the diastereoselectivity at C(20) in the formation of C(21)-fluorinated thevinols // Org Biomol Chem. – 2023. – Vol. 21, № 7. – P. 1440–1449. https://doi.org/10.1039/D2OB02144G.

35. Sirohi S., Dighe S. V., Madia P. A. et al. The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity // J Pharmacol Exp Ther. – 2009. – Vol. 330, № 2. – P. 513–519. https://doi.org/10.1124/jpet.109.152678.

36. Skolnick P. Treatment of overdose in the synthetic opioid era // Pharmacol Ther. – 2022. – Vol. 233. – P. 108019. https://doi.org/10.1016/j.pharmthera.2021.108019.

37. Skolnick P., Paavola J., Heidbreder C. Synthetic opioids have disrupted conventional wisdom for treating opioid overdose // Drug Alcohol Depend Rep. – 2024. – Vol. 12. – P. 1100268. https://doi.org/10.1016/j.dadr.2024.100268.

38. Sladojevich F., Arlow S. I., Tang P. et al. Late-stage deoxyfluorination of alcohols with PhenoFluor // J Am Chem Soc. – 2013. – Vol. 135, № 7. – P. 2470–2473. https://doi.org/10.1021/ja3125405.

39. Somerville N. J., O’Donnell J., Gladden R. M. et al. Characteristics of fentanyl overdose – Massachusetts, 2014-2016 // MMWR Mor Mortal Wkly Rep. – 2017. – Vol. 166, № 14. – P. 382–386. https://doi.org/10.15585/mmwr.mm6614a2.

40. Sorrentino J. P., Altman R. A. Fluoroalkylation of dextromethorphan improves cns exposure and metabolic stability // ACS Med Chem Lett. – 2022. – Vol. 13, № 4. – P. 707–713. https://doi.org/10.1021/acsmedchemlett.2c00055.

41. Sorrentino J. P., Ambler B. R., Altman R. A. Late-stage conversion of a metabolically labile aryl methyl ether-containing natural product to fluoroalkyl analogues // J Org Chem. – 2020. – Vol. 85, № 8. – P. 5416–5427. https://doi.org/10.1021/acs.joc.0c00125.

42. Strauss D. G., Li Z., Chaturbedi A. et al. Intranasal naloxone repeat dosing strategies and fentanyl overdose: a simulation-based randomized clinical trial // JAMA Netw Open. – 2024. – Vol. 7, № 1. – P. e2351839. https://doi.org/10.1001/jamanetworkopen.2023.51839.

43. Strickland J. C., Marks K. R., Smith K. E. et al. Patient perceptions of higher-dose naloxone nasal spray for opioid overdose // Int J Drug Policy. – 2022. – Vol. 106. – P. 103751. https://doi.org/10.1016/j.drugpo.2022.103751.

44. Takemori A. E., Hayashi G., Smits S. E. Studies on the quantitative antagonism of analgesics by naloxone and diprenorphine // Eur J Pharmacol. – 1972. – Vol. 20. – P. 85–92. https://doi.org/10.1016/0014-2999(72)90219-1.

45. Todaro D. R., Volkow N. D., Langleben D. D. et al. Collateral damage: neurological correlations of non-fatal overdose in the era of fentanyl-xylazine // Neurosci Insights. – 2024. – Vol. 19. – P. 1–4. https://doi.org/10.1177/26331055241247156.

46. Trøstheim M., Eikemo M., Haaker J. et al. Opioid antagonism in humans: a primer on optimal dose and timing for central mu-opioid receptor blockade // Neuropsychopharmacology. – 2023. – Vol. 48, № 2. – P. 299–307. https://doi.org/10.1038/s41386-022-01416-z.

47. Unna K. Antagonistic effect of N-allylnormorphine upon morphine // J Pharmacol Exp Ther. – 1943. – Vol. 79. – P. 2–31.

48. Volkow N., Collins F. The role of science in addressing the opioid crisis // N Engl J Med. – 2017. – Vol. 377, № 4. – P. 391–394. https://doi.org/10.1056/NEJMsr1706626.

49. Wang D. S., Sternbach G., Varon J. Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine // J Emerg Med. – 1998. – Vol. 16, № 3. – P. 471–475. https://doi.org/10.1016/s0736-4679(98)00019-5.

50. Watson W. A., Steele M. T., Muelleman R. L. et al. Opioid toxicity recurrence after an initial response to naloxone // J Toxicol Clin Toxicol. – 1998. – Vol. 36, № 1–2. – P. 11–17. https://doi.org/10.3109/15563659809162577.

51. Winstanley E. L., Mahoney J. J. 3rd, Castillo F. et al. Neurocognitive impairments and brain abnormalities resulting from opioid-related overdoses: a systematic review // Drug Alcohol Depend. – 2021. – Vol. 226. – P. 108838. https://doi.org/10.1016/j.drugalcdep.2021.108838.

52. Zamora J. C., Smith H. R., Jennings E. M. et al. Long-term antagonism and allosteric regulation of mu opioid receptors by the novel ligand, methocinnamox // Pharmacol Res Perspect. – 2021. – Vol. 9, № 6. – P. e00887. https://doi.org/10.1002/prp2.887.

53. Zelentsova M. V., Sandulenko I. V., Ambartsumyan A.A. et al. C(21)-Diand monofluorinated scaffold for thevinol/orvinol-based opioid receptor ligands // Org Biomol Chem. – 2023. – Vol. 21, № 45. – P. 9091–9100. https://doi.org/10.1039/D3OB01577G.

54. Zhou Y., Wang J., Gu Z. et al. Next generation of fluorine-containing pharmaceuticals, compounds currently in phase II–III clinical trials of major pharmaceutical companies: new structural trends and therapeutic areas // Chem Rev. – 2016. – Vol. 116, № 2. – P. 422–518. https://doi.org/10.1021/acs.chemrev.5b00392.